Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia

被引：4

作者：

Wang, Jianxiang ^{[1
]}

Jiang, Bin ^{[2
]}

Li, Jian ^{[3
]}

Liu, Ligen ^{[4
]}

Du, Xin ^{[5
]}

Jiang, Hao ^{[6
]}

Hu, Jianda ^{[7
]}

Yuan, Menghe

Sakatani, Taishi ^{[8
]}

Kadokura, Takeshi ^{[9
]}

Takeuchi, Masato ^{[9
]}

Izuka, Shunsuke ^{[9
]}

Girshova, Larisa ^{[10
]}

Tan, Jerome ^{[11
]}

Bondarenko, Sergey N. ^{[12
]}

Wong, Lily L. L. ^{[13
]}

Khuhapinant, Archrob ^{[14
]}

Martynova, Elena ^{[15
]}

Hasabou, Nahla ^{[16
]}

Tiu, Ramon V. ^{[16
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China

[2] Peking Univ Int Hosp, Dept Hematol, Beijing, Peoples R China

[3] Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China

[4] Shanghai Tongren Hosp, Dept Hematol, Shanghai, Peoples R China

[5] Guangdong Prov Peoples Hosp, Dept Hematol, Guangzhou, Peoples R China

[6] Peking Univ Peoples Hosp, Dept Hematol, Beijing, Peoples R China

[7] Fujian Med Univ Union Hosp, Fujian Inst Hematol, Fuzhou, Fujian, Peoples R China

[8] Astellas Pharma Inc, Beijing, Peoples R China

[9] Astellas Pharma Inc, Tokyo, Japan

[10] Almazov Natl Med Res Ctr, St Petersburg, Russia

[11] Univ Malaysia Sarawak, Fac Med & Hlth Sci, Dept Med, Dept Hematol,Ampang Hosp Selangor, Sarawak, Malaysia

[12] State Med Univ, Clin Res Inst Pediat Hematol & Transplantat Name, St Petersburg, Russia

[13] Queen Elizabeth Hosp, Dept Hematol, Kota Kinabalu, Sabah, Malaysia

[14] Mahidol Univ, Fac Med Siriraj Hosp, Div Hematol, Dept Med, Bangkok, Thailand

[15] Skolkovo Inst Sci & Technol, Moscow, Russia

[16] Astellas Pharma Inc, Northbrook, IL USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-145436

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

695

引用

页数：4

共 50 条

[21] A phase III randomized study of gilteritinib versus salvage chemotherapy in FLT3 mutation-positive subjects with relapsed or refractory acute myeloid leukemia
Wang, J.
Li, J.
Tantiworawit, A.
Izuka, S.
Yamada, S.
Hill, J.
Rich, E. Shima
Bahceci, E.
ANNALS OF ONCOLOGY, 2018, 29
[22] A phase 3, open-label, randomized study of the FLT3 inhibitor gilteritinib versus salvage chemotherapy in adults with first relapse or primary refractory FLT3 mutation-positive acute myeloid leukemia.
Perl, Alexander E.
Cortes, Jorge E.
Strickland, Stephen Anthony
Ritchie, Ellen K.
Neubauer, Andreas
Martinelli, Giovanni
Naoe, Tomoki
Pigneux, Arnaud
Rousselot, Philippe H.
Rollig, Christoph
Baer, Maria R.
Larson, Richard A.
James, Angela Joubert
Chen, Caroline
Shu, Lei
Hasabou, Nahla
Bahceci, Erkut
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[23] Gilteritinib for the treatment of patients with FLT3 mutated relapsed or refractory acute myeloid leukemia
Wang, Eunice S.
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2019, 4 (03): : 105 - 112
[24] Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia
Chen, Nianci
Pan, Jiajia
Zhou, Yile
Mao, Liping
Lou, Yinjun
Qian, Jiejing
Xu, Gaixiang
Wei, Juying
Zhou, De
Shou, Lihong
Huang, Li
Yan, Minchao
Zeng, Hui
Fan, Cuihua
Wu, Gongqiang
Feng, Weiying
Tong, Hongyan
Jin, Jie
Wang, Huafeng
BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (03) : 861 - 870
[25] Gilteritinib prolongs survival in patients with FLT3-mutated relapsed/refractory AML: phase 3 ADMIRAL trial results
Perl, Alexander E.
Martinelli, Giovanni
Cortes, Jorge E.
Neubauer, Andreas
Berman, Ellin
Paolini, Stefania
Montesinos, Pau
Baer, Maria R.
Larson, Richard A.
Ustun, Celalettin
Fabbiano, Francesco
Di Stasi, Antonio
Stuart, Robert
Olin, Rebecca
Kasner, Margaret
Ciceri, Fabio
Chou, Wen-Chien
Podoltsev, Nikolai
Recher, Christian
Yokoyama, Hisayuki
Hosono, Naoko
Yoon, Sung-Soo
Lee, Je-Hwan
Pardee, Timothy
Fathi, Amir T.
Liu, Chaofeng
Liu, Xuan
Bahceci, Erkut
Levis, Mark J.
SWISS MEDICAL WEEKLY, 2019, 149 : 3S - 4S
[26] A SYSTEMATIC REVIEW OF THE HUMANISTIC BURDEN OF FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Casamayor, M.
Gubbels, L.
Garnham, A.
Shah, M., V
VALUE IN HEALTH, 2020, 23 : S29 - S29
[27] ESTIMATION OF HEALTH STATE UTILITIES IN FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Cella, D.
Qi, C. Z.
Yang, H.
Garnham, A.
Shah, M., V
VALUE IN HEALTH, 2020, 23 : S77 - S78
[28] Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia
Fathi, Amir Tahmasb
Arevalo, Mabel
Gutierrez, Sonia
Molero, Antonieta
Sacilotto, Natalia
Limon, Ana E.
Faller, Douglas V.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[29] Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia
McCall, David
Roth, Michael
Mahadeo, Kris M.
Toepfer, Laurie
Nunez, Cesar
Short, Nicholas J.
Daver, Naval
Kadia, Tapan M.
DiNardo, Courtney
Yi, Joanna S.
Cuglievan, Branko
BLOOD ADVANCES, 2021, 5 (23) : 5215 - 5219
[30] Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Cortes, Jorge E.
Khaled, Samer
Martinelli, Giovanni
Perl, Alexander E.
Ganguly, Siddhartha
Russell, Nigel
Kraemer, Alwin
Dombret, Herve
Hogge, Donna
Jonas, Brian A.
Leung, Anskar Yu-Hung
Mehta, Priyanka
Montesinos, Pau
Radsak, Markus
Sica, Simona
Arunachalam, Meena
Holmes, Melissa
Kobayashi, Ken
Namuyinga, Ruth
Ge, Nanxiang
Yver, Antoine
Zhang, Yufen
Levis, Mark J.
LANCET ONCOLOGY, 2019, 20 (07): : 984 - 997

← 1 2 3 4 5 →